If patient is doing well, why to change treatment at all ?
Data about current Interferon treatment of viral illness like SARS-Cov2 are rare, and most data about use of IFN originate quite time ago. Chinese did not report frequent number of patients treated with IFN in COVID19 according to published information in peer sources, except different press. On the other side we as hematologist know that even in best scenario IFN is not working well for large bulk of CML patients and in all our guidance is not recommended INF except in trials.
Moreover we have data about effects of imatinib in immune modulation, isn't it (ICMLF correspondence)?
Another information to patients (it is probably important to provide part of this correspondence to CML advocates as well) is that side effects of interferon are sometimes quite similar to CODIV19. Moreover interferon supplies in Europe are cut by stopping of its production by Roche in last year. In Eastern Europe we have not seen IFN for almost a year due to vendors.
Best for all of our patients is keep personal distance, home isolation and regular therapy with current TKI , not to have patients loosing their previous response.
For those who tackle Cov2 infection, we will work with infection medicine specialists to save their life.